The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...

THOUSAND OAKS, Calif. and BRUSSELS, April 1, 2017/ PRNewswire/-- Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of ...

The U.S. Food and Drug Administration has approved a drug treatment specifically for postmenopausal women with a high risk of breaking bones. Doses are taken in two back-to-back injections ...

(Reuters) - Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug ...

(Reuters) - The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture. Postmenopausal ...

EVENITY has been studied for its potential to reduce the risk of fractures in an extensive global Phase 3 program that included two large fracture trials comparing EVENITY to either placebo or active ...

I’ve never discussed romosozumab (Evenity), which was approved in 2019 by the Food and Drug Administration after trials showed that it reduced fractures compared with placebo or alendronate (Fosamax).

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo.